IQVIA子公司发行20亿美元2034年到期高级票据（票息6.375%）完成定价，用于全额赎回2026年5.000%票据并偿还部分循环信贷

----- d516985d8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 9, 2026
IQVIA HOLDINGS INC.
(Exact name of registrant as specified in its charter)
Delaware
001-35907
27-1341991
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2400 Ellis Road
Durham
,
North Carolina
27703
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
(919)
998-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol
Name of Each Exchange
on which Registered
Common Stock, par value $0.01 per share
“
IQV
”
New York Stock Exchange
Item 8.01
Other Events
On September 9, 2026, IQVIA Holdings Inc. (the “Company”) issued a press release announcing that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2034 (the “Notes Offering”) and intends to use the proceeds to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.
On September 9, 2026, the Issuer entered into a purchase agreement with the representative of the purchasers named therein, relating to the issuance and sale of $2,000,000,000 in aggregate principal amount of senior notes due 2034 bearing interest at a rate of 6.375% per annum. The consummation of the Notes Offering, which is expected to occur on or about September 23, 2026, is subject to the satisfaction of customary closing conditions. The Company also issued a press release announcing the pricing of the Notes Offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form
8-K.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits.
Exhibit
No.
Description
99.1
Launch press release dated September 9, 2026
99.2
Pricing press release dated September 9, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 9, 2026
IQVIA HOLDINGS INC.
By:
/s/ Eric M. Sherbet
Eric M. Sherbet
Executive Vice President and General Counsel

----- d516985dex991.htm -----
EX-99.1
2
d516985dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
IQVIA Announces Offering of Senior Notes
September 9, 2026
RESEARCH
TRIANGLE
PARK,
N.C.
– IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through
an offering of senior notes due 2034 (the “Notes”).
The proceeds from the Notes offering will be used to redeem in full the Issuer’s
Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to
market and other customary conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor
shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The
Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to
non-U.S.
investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global
provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence
™
to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI
®
, advanced analytics, the latest
technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with
AI-powered
capabilities built on
best-in-class
approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by
the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of
innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other
healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Forward Looking Statements
Certain statements in this
press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual
results to differ materially.
IQVIAFIN
Kerri
Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973-541-3558

----- d516985dex992.htm -----
EX-99.2
3
d516985dex992.htm
EX-99.2
EX-99.2
Exhibit 99.2
IQVIA Announces Pricing of Senior Notes
September 9, 2026
RESEARCH TRIANGLE PARK, N.C.
– IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the
“Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to
pay fees and expenses related to the Notes offering.
The Notes will bear interest at a rate of 6.375% per annum and will pay interest semi-annually in
arrears on March 15 and September 15 of each year, beginning on March 15, 2027. The Notes will mature on March 15, 2034, unless earlier repurchased or redeemed in accordance with their terms. The issuance of the Notes is expected
to occur on or about September 23, 2026, subject to the satisfaction of customary closing conditions.
This press release does not constitute an
offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered
have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable
exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and
outside the United States only to
non-U.S.
investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global
provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence
™
to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI
®
, advanced analytics, the latest
technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with
AI-powered
capabilities built on
best-in-class
approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by
the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of
innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other
healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Forward Looking Statements
Certain statements in this
press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual
results to differ materially.
IQVIAFIN
Kerri
Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973-541-3558